Structure via PubChem · Public domain (PubChem)
imeglimin
Sign in to saveImeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication. It was approved for use in Japan in June 2021.
Chemical data
- Formula
- C6H13N5
- Molecular weight
- 155.2 g/mol
- IUPAC name
- (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine
- SMILES
- C[C@@H]1N=C(NC(=N1)N(C)C)N
- InChIKey
- GFICWFZTBXUVIG-SCSAIBSYSA-N
- XLogP
- -1
- Polar surface area
- 66 Ų
- H-bond donors
- 2
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 155.117
Show 3 more facts
- chemical formula
- C₆H₁₃N₅
- isomeric SMILES
- C[C@@H]1N=C(NC(=N1)N(C)C)N
- canonical SMILES
- CC1N=C(NC(=N1)N(C)C)N
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication. It was approved for use in Japan in June 2021.
It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.
Excerpted from Wikipedia’s “imeglimin” article, available under the CC BY-SA 4.0 licence.